Non-Cystic Fibrosis Bronchiectasis Market Thrives On Surging Respiratory Disease Cases: Core Growth Enabler in the Non-Cystic Fibrosis Bronchiectasis Market, 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Non-Cystic Fibrosis Bronchiectasis Industry Market Size Be by 2025?
In recent times, the market size for non-cystic fibrosis bronchiectasis has witnessed considerable growth. The market, valued at $3.5 billion in 2024, is projected to rise to $3.74 billion in 2025 with a compound annual growth rate (CAGR) of 6.9%. The growth in the past years can be credited to an increase in disease occurrence and prevalence, advancements in diagnostic technologies, an enlarging older population, governmental backing and funding, enhancements in healthcare structure, growth in diagnosis awareness, an expanding older population, and environmental exposure.

What's the Long-Term Growth Forecast for the Non-Cystic Fibrosis Bronchiectasis Market Size Through 2029?
It is anticipated that the market size for non-cystic fibrosis bronchiectasis will witness notable advancement in the upcoming years, reaching $4.82 billion in 2029 with a 6.6% compound annual growth rate (CAGR). This expected growth during the forecast period can be credited to the progress in personalized medicine, the advent of novel biomarkers, escalating investments in respiratory medicine, rising research and development activities, public health endeavors, the worldwide aging populace, and the creation of specialized treatments. Key trends for the forecast period include digital health innovations, emphasis on targeted treatments, the incorporation of Artificial Intelligence (AI) and machine learning, the transition towards care at home, a patient-oriented approach, and the expansion of mobile health (mHealth) solutions.

View the full report here:
https://www.thebusinessresearchcompany.com/report/non-cystic-fibrosis-bronchiectasis-global-market-report

What Are the Key Growth Drivers Fueling the Non-Cystic Fibrosis Bronchiectasis Market Expansion?
The escalating occurrence of respiratory illnesses is projected to spur the expansion of the non-cystic fibrosis bronchiectasis market in the future. A variety of conditions impacting the lungs and respiratory system, which affect breathing and overall respiratory functionality, are comprised within respiratory diseases. Rising environmental pollution, including toxins from both outdoor and indoor sources like cigarette smoke, is a major contributor to the increasing incidence of these diseases. This rise in prevalence opens opportunities for progress in understanding, diagnosing, and management of non-cystic fibrosis bronchiectasis, through the implementation of focused interventions and public health endeavors. For example, in June 2023, a report by the Office for Health Improvement and Disparities, a UK government entity, revealed that a total of 4,622 notifications of scarlet fever Group A Streptococcus bacteria were received from week 37 to week 46 during the 2022-2023 period in England, with 851 notifications received in just week 46. This figure far exceeds the average of 1,294 notifications (varying from 258 to 2,008) for the identical period over the preceding five years. As such, the climbing prevalence of respiratory diseases is set to bolster the growth of the non-cystic fibrosis bronchiectasis market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17209&type=smp

What Are the Key Trends Driving Non-Cystic Fibrosis Bronchiectasis Market Growth?
Major actors in the non-cystic fibrosis bronchiectasis market, such as Zambon S.P.A. have started turning their attentions towards personalized medicine techniques like nebulization solutions. Such approaches are aimed at improving the efficacy of drug delivery and patient adherence to treatment regimes. Nebulization solutions, through their advanced technical make-up, allow for the precise and effective dispersion of respiratory medications which incr heightens patient adherence and boosts overall treatment results. Focusing on Zambon's recent activities, for example, the Italy-based global pharmaceutical firm gained a US FDA designation for its CMS I-neb therapy for non-cystic fibrosis bronchiectasis (NCFB) patients in April 2022. CMS I-neb, currently an experimental treatment, is being designed to be the first of its kind in inhaled therapies to tackle adult NCFB colonised with P. aeruginosa - a chronic, progressive, and permanent respiratory illness. This breakthrough designation confirms the registration pathway for CMS I-neb in NCFB treatment, and may possibly speed up its development and review process.

How Is the Non-Cystic Fibrosis Bronchiectasis Market Segmented?
The non-cystic fibrosis bronchiectasis market covered in this report is segmented -

1) By Diagnosis: Computed Tomography (CT) Scan, Bronchoscopy, Chest X Ray, Lung Function, Sputum Culture Test, Blood Tests, Other Diagnosis Types
2) By Treatment: Surgery, Physiotherapy, Vaccination, Airway Pharmacotherapy, Antibiotics, Other Treatments
3) By End Use: Hospitals And Clinics, Ambulatory Care Centers, Other End Uses

Subsegments:
1) By Computed Tomography (CT) Scan: High-Resolution CT (HRCT), Standard CT
2) By Bronchoscopy: Flexible Bronchoscopy, Rigid Bronchoscopy
3) By Chest X-Ray: Standard Chest X-Ray, Digital Chest X-Ray
4) By Lung Function: Spirometry, Peak Flow Measurement
5) By Sputum Culture Test: Bacterial Culture, Fungal Culture, Viral Culture
6) By Blood Tests: Complete Blood Count (CBC), C-Reactive Protein (CRP), Immunoglobulin Levels
7) By Other Diagnosis Types: Sweat Test, Genetic Testing, Exhaled Nitric Oxide Test

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=17209&type=smp

Which Companies Are Leading the Charge in Non-Cystic Fibrosis Bronchiectasis Market Innovation?
Major companies operating in the non-cystic fibrosis bronchiectasis market are Pfizer Inc., F Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc (GSK), Boehringer Ingelheim International GmbH, Viatris Inc, Teva Pharmaceutical Industries Ltd, Vertex Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma Ltd, Dr Reddy's Laboratories Ltd, Chiesi Farmaceutici SpA, Lupin Limited, Zambon Company SpA, Sunovion Pharmaceuticals Inc, Insmed Incorporated, Genentech, Zydus Cadila, Santhera Pharmaceuticals, TSRL Inc

Which Regions Are Leading the Global Non-Cystic Fibrosis Bronchiectasis Market in Revenue?
North America was the largest region in the non-cystic fibrosis bronchiectasis market in 2023. The regions covered in the non-cystic fibrosis bronchiectasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17209

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.